Sargent Investment Group LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 21st, 2023

Sargent Investment Group LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,694 shares of the company’s stock after purchasing an additional 85 shares during the quarter. Johnson & Johnson comprises approximately 1.4% of Sargent Investment Group LLC’s portfolio, making the stock its 17th biggest position. Sargent Investment Group LLC’s holdings in Johnson & Johnson were worth $4,539,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P raised its position in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. raised its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. raised its position in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its stake in Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Piper Sandler decreased their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Morgan Stanley increased their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Raymond James cut their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group started coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective on the stock. Finally, Atlantic Securities lowered their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $163.58 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $157.48 and a two-hundred day moving average price of $166.96. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69. The company has a market cap of $426.01 billion, a P/E ratio of 24.27, a PEG ratio of 2.75 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $2.67 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.64 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.